Congressional Mitochondrial Disease Caucus briefing to explore how FDA drug review processes affect patient care and access for ultra-rare, life-threatening pediatric mitochondrial diseases, using pyruvate dehydrogenase complex deficiency (PDCD) as an example. WASHINGTON, Feb. 16, 2026…
Source link
















Leave a Reply